Didier Verhoeven

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

Angelo Di Leo, Guy Jérusalem, Luboš Petruželka et al. · Journal of Clinical Oncology · 2010 · 633 citations · Full text

Medicine, Oncology, Pharmacology +16

Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial

Angelo Di Leo, Guy Jérusalem, Luboš Petruželka et al. · JNCI Journal of the National Cancer Institute · 2013 · 328 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Lowell L. Hart, Renata Ferrarotto, Zoran Andrić et al. · Advances in Therapy · 2020 · 125 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

Emmanuel Seront, Sylvie Rottey, Brieuc Sautois et al. · Annals of Oncology · 2012 · 124 citations · Full text

Medicine, Oncology, Pharmacology +14

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 122 citations

Medicine, Gynecology, Oncology +13